Bristol-Myers Squibb Company (BMY) - Stock Analysis
Last updated: Apr 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Compelling short-term upside driven by multiple recent catalysts including strong Q4 2025 sales beat, raised 2026 guidance, regulatory approvals for key drugs, advancing clinical pipeline with upcoming pivotal data, and solid technical momentum showing a 13% price rise over 21 days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High profitability ⢠Elevated leverage ⢠Strong cash flow BristolâMyers Squibb delivers strong 2025 profitability and cash generation supporting dividends but is constrained by high leverage, large intangibles and a relatively high payout ratio.
Price Behavior
Key Price Behavior Insights: ⢠Neutral momentum ⢠Nearby support ⢠Clear resistance Support Level: $56.40â$56.90 Resistance Level: $59.50â$61.70 BMY is trading essentially flat over the last month, sitting midârange with nearby support around $56.40â$56.90 and resistance at $59.50â$61.70âclear breakout above ~61 needed to resume a stronger uptrend.
Sentiment & News
Key News Insights: ⢠Institutional inflows ⢠Dividend/yield thesis ⢠Opdivo patent upside Investors and institutions have broadly increased stakes in Bristol Myers Squibb amid solid growth, dividend/yield appeal, and supportive product/pipeline developments (notably Opdivo patent potential), though some trims signal mixed positioning.
AI Summary
BMY should be viewed as a recovery/transition tradeâpriced like a lowâmultiple dividend stock today but offering high upside optionality if upcoming pivotal readouts (Opdivo/Qvantig lifecycle, ADEPT, iberdomide) convert into sustained doubleâdigit growthâwhile the key downside is that its high absolute leverage plus concentrated binary clinical risk could force impairments, dividend pressure, or curtailed buybacks if those readouts fail.
Description
Bristol-Myers Squibb is a global biopharmaceutical company that researches, develops, licenses, manufactures and markets medicines across oncology, hematology, cardiovascular, immunology, fibrosis, neuroscience and infectious disease. Its commercial portfolio includes oral and biologic therapies for cancer, cardiovascular and immune-mediated conditions, with widely used products such as Eliquis and Opdivo, and it sells through wholesalers, pharmacies, hospitals and government channels. Founded in 1887, the company is headquartered in New York, New York.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 9 | Feb 16 | BMY | Bristol-Myers Squibb Company | Compelling short-term upside driven by multiple recent catalysts including strong Q4 2025 sales beat, raised 2026 guidance, regulatory approvals for key drugs, advancing clinical pipeline with upcoming pivotal data, and solid technical momentum showing a 13% price rise over 21 days. | Closed | -0.1% |
| Dec 23 | Dec 30 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb (BMY) benefits from 17% Q3 portfolio growth, upcoming FDA review and clinical data catalysts, strong operational turnaround with positive earnings and cash flow, and sustained 17% stock gain over 21 days with technical momentum. Its diversified oncology portfolio and dividend appeal underpin a strong near-term growth case. | Closed | -0.1% |
| Dec 4 | Dec 11 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb shows compelling near-term upside with strong Q3 revenue and raised guidance, notable clinical/regulatory catalysts (FDA Fast Track, Phase 3 trials), substantial debt reduction, and technical breakout signaling positive momentum. | Closed | -1.4% |